In-house members
15
Total footprint
30,000sq ft
Our Old Market incubator hosts growing Deep Tech companies that have moved beyond proof of concept and are scaling their teams, typically 20–30 people strong.
This site serves as the main event venue of our Bristol campus — featuring the 1023 Bar, our community’s main stage for events and a gathering spot for informal meetups every Thursday.
Old Market members are breaking new ground in several science and engineering fields — from advanced sustainable materials to vaccine platforms and stem cell therapeutics.
With 30,000 sq ft of laboratory, office and meeting space, our Old Market incubator is a supportive, well-connected hub for growing Deep Tech companies.
This location also features a large event space, shared social spaces, and our favourite addition — the 1023 Bar, open every Thursday for the community.
Membership includes access to our platform of support, providing opportunities to attend workshops and events, connect with other founders, and find a mentor.
If you are looking for private lab and office space, get in touch to enquire about our current availability at Old Market or explore OMX, our third Bristol incubator, set to open in 2026.
Travel between locations is measured in walking distance
Midland Rd & St Philips Rd
0.5 miles / 11 min
0.7 miles / 15 min
Lifecare is committed to improving the lives of people and pets with diabetes. It is developing the next-generation of miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers to the market. The company’s spin-off entity Lifecare Chemistry Ltd was founded to enhance research collaboration and secure ownership of its improved analyte-specific chemical receptor developments.
Carbometrics is striving to improve diabetes patient care by enhancing technology for continuous glucose monitoring. The team aims to pave the way for a new class of highly-accurate sensors with its groundbreaking synthetic molecule that is both chemically stable and able to bind to glucose in the blood. This follows on from the work of exited startup Ziylo Ltd, which was Science Creates’ very first resident and acquired by Novo Nordisk in 2018.
neo-fossil is developing new technology using cell engineering to help reverse the threat of climate change. By optimising biology, it is creating new fossils that harvest atmospheric carbon dioxide, storing it for centuries.
Invivo Healthcare is developing solutions to better understand and modulate human microbiomes, promoting long-term wellness and a sustainable future of healthcare. Its supplement therapeutics are plant, nutrient and microorganism-based, designed to lead the way in combating the rise of chronic diseases and a reductionist approach to medicine.
Herd Climate is a not-for-profit addressing the pressing agricultural challenge of enteric methane emissions produced by farming animals. It works directly with farmers, researchers and young people to bridge the gap between climate-smart scientific advancements and on-the-ground practices through innovative research, accessible science communication and engaging networking events. This equips agricultural communities - who are at the forefront of climate solutions - with actionable insights for collaborative, sustainable farming practices.
NuNano is advancing the field of atomic force microscopy with high-precision probes for nanometer-scale imaging. Its proprietary microfabrication processes produce reliable, high-quality probes with market-leading dimensional tolerances. It also provides dedicated support to its customers, from probe selection to storage, for a seamless user experience.
Reach Industries is optimising lab and scientist efficiency with its Lumi™ visual intelligence platform. By automating data capture and analysis for experiments, observations and complex scientific workflows, the platform functions as a streamlined operating system that is accelerating R&D, improving compliance and increasing reproducibility.
neo-fossil is developing new technology using cell engineering to help reverse the threat of climate change. By optimising biology, it is creating new fossils that harvest atmospheric carbon dioxide, storing it for centuries.
GenomeKey is transforming how healthcare clinicians diagnose and treat infections like sepsis to improve patient outcomes. Using cutting-edge machine learning and DNA sequencing, the company is developing a next-generation diagnostic device to identify bacterial genomes and determine their antimicrobial susceptibility directly from patient blood in just a few hours, rather than days. This enables clinicians to prescribe the right antibiotics for patients with much more efficiency and accuracy, reducing costs, minimising unnecessary antibiotic use and ultimately saving millions of lives from the world’s leading cause of death.
.webp)